General Mills GIS
Consumer Defensive · Packaged Foods · Synthos Deep Dive · 2026-07-03
The Overview
General Mills makes the food in the middle aisles of the grocery store — Cheerios, Betty Crocker, Pillsbury, Nature Valley, Häagen-Dazs, Old El Paso, Progresso, Totino's, and Blue Buffalo pet food. It's a big, old, stable company. The problem: shoppers are buying less of this kind of packaged food (organic sales fell 2% last year), so the business is slowly shrinking, not growing.
The stock is cheap — you pay about $11 for every $1 of yearly adjusted profit, and it pays a fat 6.5% dividend. But it's cheap for a reason: profits are flat-to-falling, and last year the company had to write down $1.8 billion because some of the brands it bought are worth less than it paid. Our verdict is Watch — not a buy, not a sell. If you want a steady dividend check and can accept a stock that mostly goes sideways, it's defensible; if you want your money to grow, look elsewhere.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a little riskier than average). The stock barely moves with the market (good), and it's cheap (good) — but the company owes a lot of money relative to its earnings, and its business is slowly shrinking (both bad).
- Growth Quality 3/10 (poor). Sales and profits are flat-to-down. There is very little growth here.
- Exponential Potential 1/10 (essentially none). This is a mature company in a category that is stagnant. Do not expect the stock to multiply.
The one big worry: people keep buying less center-store packaged food, and General Mills carries a lot of debt. If profits and cash flow keep sliding, the generous dividend — the main reason to own it — could eventually be at risk.
Putting a number on it: our fair-value estimate is $37 against a current price of $41.55 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Cheap (~11x adj EPS) & low-beta, but 4x net-debt/EBITDA, a huge FY26 impairment, and secular volume decline cap the safety.
Flat-to-down revenue and EPS through FY30E; organic sales -2% FY26; margins eroding; no earnings growth to underwrite.
Zero acceleration — a mature, decelerating packaged-food compounder in a shrinking category. Structurally not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Zero acceleration — a mature, decelerating packaged-food compounder in a shrinking category. Structurally not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $36.67 (high $47 / low $30; 0 Strong Buy · 8 Buy · 22 Hold · 6 Sell → Hold) — context, not our anchor |
| Valuation | GAAP EPS negative (FY26 impairment) · ~11× adj FY26 EPS ($3.55) · ~11× FY27E · EV/S 1.8× · P/FCF ~12× · div yield ~6.5% |
| Technicals | Downtrend — $37.57, −30% off 52-wk high, below the 200-DMA ($42.3), above 50-DMA, RSI 69, −29% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices in KB; call rests entirely on fundamentals, valuation, and quant |
| Position sizing | Income/defensive satellite only, ~1–2% if held for the yield; not a core growth holding |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for GIS — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $41.55, 12% above the 50-day average ($37), 4% above the 200-day average ($40) — an uptrend. 19% below the 52-week high of $51, 29% above the 52-week low of $32.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $41.55 is currently inside the band (band $35–$42).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 67.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.22, positive momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = GIS · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
General Mills (NYSE: GIS), founded 1866 and headquartered in Minneapolis, is a global packaged-foods maker. Its brand portfolio spans breakfast cereal (Cheerios, Chex, Lucky Charms), baking (Betty Crocker, Pillsbury, Gold Medal), snacks (Nature Valley, Fruit Roll-Ups, Chex Mix, Gardetto's), convenient meals (Old El Paso, Progresso, Totino's), super-premium ice cream (Häagen-Dazs), and a large pet segment (Blue Buffalo, acquired 2018). Fiscal year ends late May.
The FY26 GAAP results reported 2026-07-01 were messy: a net loss of $88M (−$0.16 EPS) for the full year, driven by $1.8B of non-cash goodwill/brand-intangible impairment (rising discount rates) and a $1.0B non-cash valuation loss on the planned Brazil divestiture — plus a $1.0B gain on the North American Yogurt divestiture the other way. The cleaner number management points to is adjusted diluted EPS of $3.55 (down 16% in constant currency). Revenue $18.42B, −5% (with a 6-pt divestiture headwind and 2-pt benefit from the 53rd week); organic net sales −2%.
Revenue mix (from FMP segmentation):
- By product (FY26): Snacks $4.14B · Cereal $3.09B · Convenient meals $2.87B · Pet $2.77B · Dough $2.40B · Baking mixes/ingredients $1.93B · Super-premium ice cream $0.78B · (Yogurt down to $0.10B after the FY26 US divestiture). Snacks and cereal are the two anchors; Pet is the growth pocket (+6% FY26 reported).
- By geography (FY26 US GAAP segments): North America Retail $10.57B · North America Foodservice $2.17B · plus International and Pet reported separately. FY25 split was United States $15.78B (81%) vs Non-US $3.71B (19%) — a heavily US-domestic business.
The story is a portfolio-reshaping defensive: divesting slower assets (US/Canada yogurt, Brazil), bolting on pet (Whitebridge), and leaning on cost savings to defend margins while the core decelerates.
2. The expert thesis
There is no expert coverage of GIS in the Synthos knowledge base — total_claims is 0, with 0 net-bullish voices. No independent analyst or investor voice we track has published a thesis on this name. Accordingly, this deep dive carries no conviction-track weight; the verdict is entirely fundamentals-, valuation-, and quant-driven, and we say so plainly rather than manufacture conviction. Fabricated conviction is structurally impossible here (there are no claim_ids to cite, and we cite none).
What the data says in lieu of expert voices: this is a classic deep-value / high-yield defensive with a secular-decline overhang. The Street itself is lukewarm — 22 of 36 analysts rate it Hold, consensus is a "Hold," and the FMP letter rating is C (overall score 2/5), dragged down by weak returns-on-capital and leverage scores. Nothing in the price or the estimates argues for a growth thesis.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Cheap (~11× adj EPS) and near-zero beta (−0.05) cushion the downside, but ~4× net-debt/EBITDA, a fresh $1.8B impairment, negative GAAP earnings, and secular volume decline are real structural flags. A −29% 12-mo drawdown shows the "safe" defensive still bled. |
| Growth Quality | 3 · Poor | Revenue flat-to-down through FY30E (~$18B, no growth); adjusted EPS falling (−16% FY26) and estimates flat near ~$3.30 for years; organic sales −2%; gross margin −100bp. Pet is the only bright spot. |
| Exponential Potential | 1 · Very Low | Zero acceleration — a mature name in a stagnant-to-shrinking category. $20B cap has no TAM tailwind. Structurally the opposite of an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Accelerate strategy + $750M FY27 cost savings stabilize organic growth to flat/slightly positive; adjusted EPS recovers toward ~$3.75; multiple re-rates to ~13× as the market pays for a defended 6%+ yield. | ~$48 (+28%) |
| Base (our anchor) | Organic sales stay roughly flat; adjusted EPS ~$3.40 (in line with FY27E consensus); multiple holds ~11× — a no-growth defensive worth roughly its dividend-support value. | ~$37 (~flat) |
| Bear | Volume decline persists, promotions deepen, input inflation bites; adjusted EPS slips toward ~$3.00; multiple de-rates to ~9× and the yield's safety is questioned. | ~$28 (−25%) |
Synthos fair value = the base case, ~$37 (~flat to spot), with the full $28–$48 span as the honest range. This sits essentially on top of the Street's $36.67 consensus — a rare case where our independent model and the analyst crowd agree there is little to no upside from here, which is itself the message. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). GIS is neither an exponential nor even a strong compounder right now — it is a decelerating mature defensive:
- Forward growth: revenue CAGR FY26→FY30E is essentially 0% (~$18.4B → ~$18.3B, per FMP estimates — 2 analysts at the far end). EPS estimates are flat-to-slightly-down (~$3.40 FY26E → ~$3.10 FY27E → ~$3.30 FY30E).
- Acceleration (the 2nd derivative) is negative: organic sales went from low-single-digit growth in prior years to −2% in FY26, with North America Retail volume down double digits before price/mix. The trend is decelerating, not inflecting up.
- Room to run: the packaged-food TAM is enormous but not growing — center-store volumes are structurally soft as consumers trade to private label, fresh, and GLP-1-suppressed appetites. A $20B cap has no category tailwind to ride.
- Reinvestment runway: capital is going to cost savings, buybacks, dividends, and portfolio pruning, not to a growth engine. That is capital return, not capital compounding.
Exponential Potential: Very Low (1/10). Own GIS, if at all, for its 6.5% yield and defensive beta, never for growth or a multibagger. This honest framing is why it lands in the Watch bucket, not any growth sleeve.
5. Financials (real numbers — FMP annual/quarterly + the FY26 release)
- Revenue: FY26 $18.42B, −5% (FY25 $19.49B; FY24 $19.86B). Multi-year top-line erosion; organic −2% in FY26.
- GAAP earnings: FY26 net loss $88M, EPS −$0.16 — driven by $1.8B goodwill/brand impairment + $1.0B Brazil valuation loss, partly offset by a $1.0B yogurt-divestiture gain. Not a clean earnings year.
- Adjusted earnings (management's cut): adjusted diluted EPS $3.55, −16% cc; adjusted operating profit $2.8B, −16% cc; adjusted operating margin 15.3% (−190bp).
- Margins: gross margin 33.6% (−100bp) on higher input costs; a genuine margin-erosion trend, not one-off.
- Cash flow: FY26 operating CF $2.17B, capex −$0.54B, FCF ~$1.63B — still solidly positive and covers the dividend, but FCF fell from $2.29B (FY25) and $2.53B (FY24). FCF yield ~8%.
- Balance sheet: total debt $13.5B, net debt $13.08B. Against ~$3.3B of normalized EBITDA that is ~4× net-debt/EBITDA — elevated for a no-growth business (the FMP TTM 43× figure is distorted by the impairment-driven EBITDA collapse; use normalized). Current ratio 0.68 (thin). Goodwill + intangibles are 69% of assets — the impairment risk that just materialized is not fully behind it.
6. Valuation — cheap, or a value trap?
On adjusted earnings GIS is genuinely inexpensive: ~11× adj FY26 EPS ($3.55), ~11× FY27E (~$3.40), EV/Sales 1.8×, P/FCF ~12×, and a ~6.5% dividend yield. On GAAP it screens as loss-making because of the FY26 impairment, so the adjusted lens is the fair one. The bear's rebuttal is that cheap is the correct price for a no-growth, leveraged, secularly-challenged business — the classic value-trap setup, where the multiple stays low because earnings drift lower.
A reverse read: at ~11× flat earnings plus a ~6.5% yield, the stock is priced for roughly zero real growth in perpetuity — which is close to what the estimates show. There is no cheapness catalyst in the numbers; the re-rating case rests entirely on management stabilizing organic growth, which has not yet happened.
Street targets (context): consensus $36.67, high $47, low $30, median $36 — grades 8 Buy / 22 Hold / 6 Sell (Hold). Our ~$37 base FV is right on the consensus: independent model and crowd agree the risk/reward is roughly balanced-to-dead-money. Not a value buy at conviction — a fairly-priced defensive yield.
7. Technicals (from the tech block)
- Trend: down. $37.57 sits below the 200-DMA ($42.28) — a defined downtrend — though above the 50-DMA ($34.27) after a recent bounce. The 50 below the 200 is a death-cross posture.
- Location: −30.2% off the 52-week high ($53.83), +16.8% off the 52-week low ($32.17). Max drawdown from peak −58.5% — this "defensive" name has been a poor holding.
- Momentum: RSI(14) 68.7 — approaching overbought after the recent rally off the lows; not a low-risk entry point. MACD mildly positive (+0.73).
- Relative strength (the tell): GIS −29.4% 12-mo vs SPY +20.6% and QQQ +30.3% — massive underperformance. A +96.7% 3-mo figure reflects a bounce off a deeply depressed base, not a trend change (6-mo still −19.5%).
- Read: technicals do not support an add here — a downtrend below the 200-DMA, a large historical drawdown, and RSI near overbought after a relief rally. If anything, they argue for patience.
8. Moat & competitive position
GIS's moat is brand equity + retail distribution scale in center-store food — real but eroding. The FY26 goodwill/brand impairment is a mark-to-market admission that some of those brands are worth less than book. The structural threats are potent: private-label share gains, consumers trading to fresh/perimeter, secular cereal decline, and the emerging GLP-1 appetite-suppression overhang on packaged-snack volumes. The Pet segment (Blue Buffalo) is the best-positioned piece (+6% FY26).
Peer set (packaged food / consumer staples, market cap): Kraft Heinz $30B, Kellanova $29B, Conagra $6.9B, Hormel $13.8B, McCormick $14.4B, Archer-Daniels-Midland $37B, JBS $27B, Constellation Brands $23B, Dollar General $26B. GIS is mid-pack on size and, like most of the group, is a low-growth, high-yield defensive — the whole cohort is out of favor. GIS's ~11× adjusted multiple is roughly in line with the packaged-food peer average; it is not conspicuously cheap relative to its peers, only relative to the broad market.
9. Management, capital allocation & guidance
- Capital allocation: return-focused — $1.32B dividends and $0.50B buybacks in FY26, plus active portfolio pruning (yogurt divested, Brazil pending, Whitebridge pet added). Net debt is being paid down modestly (net debt fell from $14.9B to $13.1B). Appropriate for a low-growth cash cow, but the ~4× leverage limits flexibility.
- Insider activity: the recent Form 4s (filed 2026-07-02) are all "F-InKind" transactions — shares withheld for tax on vesting equity at $34.80, not open-market discretionary selling. No signal either way.
- Management's own guidance (half-weighted — their self-interested words). The FY26 earnings release (SEC 8-K, filed 2026-07-01) reads as a genuine release and carries real forward guidance. CEO Jeff Harmening framed FY2027 around "restoring profitable growth": with "price investment work behind us," the focus is improving topline via a step-change in brand 'remarkability' (more innovation/renovation) plus efficiency. Concretely, management targets $3 billion in cumulative cost savings by fiscal 2030 (Holistic Margin Management + global transformation), with $750 million delivered in fiscal 2027, and guided to "improved organic growth" in FY27 vs the −2% of FY26. Treat as management's self-interested framing (half-weight): the cost-savings target is credible and quantified; the "restore growth" narrative is aspirational and unproven against a −2% organic base.
10. Catalysts & what to watch
- Next earnings: 2026-09-23 (Q1'27; Street EPS $0.74, revenue ~$4.34B). The key line: organic net sales growth — does the FY27 "improved growth" guidance start to show, or does volume keep sliding?
- Cost-savings execution: the $750M FY27 / $3B-by-FY30 program — margin defense is the core of the base case.
- Brazil divestiture close: removes the writedown overhang and simplifies the portfolio.
- Dividend coverage: FCF vs the ~$1.3B dividend — the single most important safety metric for income holders.
- GLP-1 / private-label share: external secular pressures on center-store snack and cereal volumes.
Thesis tripwires (what would change the call): a second straight year of negative organic sales despite the "restore growth" plan; FCF falling below dividend coverage; a further brand impairment; or net-debt/EBITDA rising above ~4.5× — any of these would push us from Watch toward Avoid. Conversely, two quarters of positive organic growth would open a tactical case.
11. Key risks
- Secular volume decline (structural): center-store packaged food is losing share to private label, fresh, and (increasingly) GLP-1-suppressed appetites — the core headwind behind FY26's −2% organic.
- Leverage: ~4× net-debt/EBITDA on a shrinking EBITDA base; current ratio 0.68; ~$13.5B debt — limited room if margins erode further.
- Impairment risk not fully behind it: goodwill + intangibles are 69% of assets; the $1.8B FY26 charge could recur if brands keep de-rating.
- Dividend risk (the whole reason to own it): a ~6.5% yield is only attractive if it's safe; sustained FCF erosion below coverage would jeopardize it.
- Value trap: cheap can stay cheap — with no growth catalyst, the low multiple may simply track earnings lower.
- No expert coverage: zero KB voices means no independent thesis corroborates any bull case — the verdict rests solely on fundamentals and quant.
12. Verdict, position sizing & monitoring
Watch. GIS is a cheap (~11× adjusted EPS), high-yield (~6.5%), near-zero-beta packaged-food defensive — but the core business is in secular volume decline (FY26 organic −2%, a $1.8B brand impairment, adjusted EPS −16%), earnings are expected flat-to-down through FY30, the balance sheet carries ~4× leverage, and the stock has badly lagged (−29% 12-mo vs SPY +21%, below its 200-DMA). Our independent base fair value (~$37) lands right on the Street's $36.67 consensus — both say the risk/reward is roughly balanced-to-dead-money. There is no growth engine to underwrite and no expert conviction to lean on, which is why this is a Watch, not a Buy.
- Sizing: if held at all, an income/defensive satellite (~1–2%) for the yield and low beta — never a core growth position. Not a place to concentrate.
- Monitoring: re-underwrite on the §10 tripwires; the make-or-break is whether the FY27 "restore profitable growth" plan turns organic sales positive. Two straight negative-organic quarters → move toward Avoid; two positive → reconsider tactically. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $37.57.
- Single biggest risk: secular center-store decline plus ~4× leverage — the combination that could eventually pressure the dividend, the one thing holders are actually paid for.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of GIS in the Synthos knowledge base, so no
claim_ids are cited. The verdict is explicitly fundamentals-, valuation-, and quant-driven. Fabricated conviction is structurally impossible (nothing is cited that does not exist). - Data as-of: fundamentals FY26 ended 2026-05-31 (reported 2026-07-01) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: FY2027 guidance ($750M FY27 / $3B-by-FY30 cost savings, "restore profitable growth") is management's own book from the SEC 8-K, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").